netFormulary
 Report : Medicines with links to NICE 19/06/2018 05:50:05

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA 387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abraxane® 08.01.05 Formulary NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Adalimumab 13.05.03 Non Formulary NICE TA146: Psoriasis - adalimumab
Adalimumab 10.01.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab 01.05.03 Formulary NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 08.01.05 Formulary NICE TA 486: Aflibercept for treating choroidal neovascularisation
Aflibercept 08.01.05 Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 08.01.05 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 08.01.05 Formulary NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 08.01.05 Formulary NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 08.01.05 Formulary NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA 486: Aflibercept for treating choroidal neovascularisation
Alemtuzumab 08.02.03 Formulary NICE TA 312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Non Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anastrozole 08.03.04.01 Formulary NICE TA 112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 02.08.02 Formulary NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery
Apremilast 13.05.03 Non Formulary NICE TA368: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Non Formulary NICE TA372: Apremilast for treating active psoriatic arthritis
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Atezolizumab 08.01.05 Formulary NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Formulary NICE TA 399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azathioprine 10.01.03 Formulary NICE TA 480: Tofacitinib for moderate to severe rheumatoid arthritis
Baricitinib 10.01.03 Formulary NICE TA 466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA 481: Immunosuppressive therapy for kidney transplant in adults
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA 206 Bendamustine for the treatment of indolent (low grade) non-Hodgkin’s lymphoma that is refractory to rituximab
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Formulary NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Bevacizumab 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 16.01 Formulary NICE TA 285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Bevacizumab 16.01 Formulary NICE TA 214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer
Bevacizumab 16.01 Formulary NICE TA 242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pa
Bevacizumab 16.01 Formulary NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer
Bevacizumab 16.01 Formulary NICE TA 263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Bevacizumab 16.01 Formulary NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 16.01 Formulary NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Bevacizumab 16.01 Formulary NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA 450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03.02 Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.05 Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bosutinib 08.01.05 Formulary NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Non Formulary NICE TA260: Botox for migraine prophylaxis
Botulinum Toxin Type A 04.09.03 Formulary Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA 446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Cabazitaxel 08.01.05 Formulary NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
Capecitabine 08.01.03 Formulary NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Carfilzomib 08.01.05 Formulary NICE TA 457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib 08.01.05 Formulary NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Cetuximab 08.01.05 Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Ciclosporin 11.99.99.99 Non Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate inhaler 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase (Clostridium histolyticum) 10.03.01 Formulary NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Cubitan A2.03.02 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Dabigatran 02.08.02 Formulary NICE TA157: Venous thromboembolism - dabigatran
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasatinib 08.01.05 Formulary NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Formulary NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Denosumab 06.06.02 Non Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate 08.02.04 Formulary NICE TA 303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Edoxaban 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eluxadoline 01.04.02 Formulary NICE TA 471 Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Epoetin beta 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Epoetin Zeta 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Eribulin 08.01.05 Formulary NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Etanercept 13.05.03 Non Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etelcalcitide 09.05.01.02 Formulary NICE TA 448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary NICE TA 112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Exenatide prolonged release 06.01.02.03 Non Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA132: Hypercholesterolaemia - ezetimibe
Febuxostat 10.01.04 Formulary Febuxostat for the management of hyperuricaemia in people with gout (TA164)
Febuxostat 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
Fludarabine 08.01.03 Formulary NICE TA 202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab
Fludarabine 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Formulary NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Glencaprevir-pibrentasvir 05.03.03.02 Formulary NICE TA 499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA 497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
Ibrutinib 08.01.05 Formulary NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Formulary NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Idelalisib 08.01.05 Formulary NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Formulary NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA140: Ulcerative colitis (subacute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA134: Infliximab for the treatment of adults with psoriasis
Infliximab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 13.05.03 Non Formulary NICE TA134: Infliximab for psoriasis
Insulin 06.01.01.01 Non Formulary Nice web site
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Formulary NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina
Ivabradine 02.06.03 Formulary NICE TA267: Chronic heart failure - ivabradine
Ixazomib 08.01.05 Formulary NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: Multiple myeloma - lenalidomide
Lenvatinib 08.01.05 Formulary NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letrozole 08.03.04.01 Formulary NICE TA 112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Liraglutide 06.01.02.03 Formulary NICE TA203: Diabetes (type 2) - liraglutide
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Mannitol 03.07 Formulary For treating cystic fibrosis
Mannitol inhalation 03.07 Non Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Mepolizumab 03.04.02 Formulary NICE TA 431: Mepolizumab for treating severe refractory eosinophilic asthma
Methoxy Polyethylene Glycol-Epoetin Beta 09.01.03 Formulary NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Methylprednisolone 06.03.02 Formulary NICE CG8: Multiple Sclerosis; management in primary and secondary care.
Mifamurtide 08.02.04 Non Formulary NICE TA154: Hepatitis B - telbivudine
Mifamurtide 08.02.04 Formulary NICE TA 235: Mifamurtide for the treatment of osteosarcoma
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Mycophenolate Mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Mycophenolate Sodium 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Formulary NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib 08.01.05 Formulary NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis
Nivolumab 08.02.04 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Formulary NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Formulary NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma
Obeticholic acid 01.09.01 Formulary NICE TA 443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Ocriplasmin 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Formulary NICE TA202: Chronic lymphocytic leukaemia - ofatumumab
Olaparib 20 Non Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaparib 08.01.05 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA 465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Paclitaxel 08.01.05 Formulary NICE TA108: Breast cancer (early) - paclitaxel
Palbociclib 08.03.04.01 Formulary NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panobinostat 08.01.05 Formulary NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Pegasparagase 08.01 Formulary NICE TA 408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon alfa-2a 08.02.04 Formulary NICE TA 96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon alfa-2a 08.02.04 Formulary NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2a 08.02.04 Formulary NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon alfa-2a 08.02.04 Formulary NICE TA 300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon alfa-2a 08.02.04 Formulary NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA 402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Formulary NICE TA 504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182)
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.01.05 Formulary NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Non Formulary NICE TA160: quick reference guide on osteoporosis
Ranibizumab 11.08.02 Formulary NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab 11.08.02 Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Ranibizumab 11.08.02 Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Regorafenib 08.01.05 Formulary NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab 03.04.02 Formulary NICE TA 479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Formulary NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Non Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA 308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 08.02.03 Formulary NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab
Rituximab 08.02.03 Formulary NICE TA243: Follicular lymphoma - rituximab (review)
Rituximab 08.02.03 Formulary NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab
Rituximab 08.02.03 Formulary NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab
Rituximab 08.02.03 Formulary NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for treatment of DVT
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Roflumilast 03.03.03 Formulary NICE TA 461 - Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril and valsartan 02.05.05 Formulary NICE TA388
Sarilumab 10.01.03 Formulary NICE TA 485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Non Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA332: Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
Sirolimus 08.02.02 Formulary NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/velpatasvir/voxilaprevir 05.03.03.02 Formulary NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.05 Formulary NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tacrolimus 08.02.02 Formulary NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Talimogene laherparepvec 08.01.05 Formulary NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Temozolomide 08.01.05 Formulary NICE TA23: Brain cancer - temozolomide
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Tenofovir Disproxil 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Thalidomide 08.02.04 Formulary NICE TA 228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
Tocilizumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tofacitinib 10.01.03 Formulary NICE TA 480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab emtansine 08.01.05 Formulary NICE TA235: Osteosarcoma - mifamurtide
Trifluridine and tipiracil 08.01.05 Formulary NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 01.05.03 Formulary NICE TA 456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Non Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Non Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Non Formulary NICE TA313: Ustekinumab for treating active psoriatic arthritis
Ustenkinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustenkinumab 10.01.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA 342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA 352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib 08.01.05 Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Vemurafenib 08.01.05 Formulary NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Vortioxetine 04.03.03 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Non Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Sunderland Joint Formulary